GHENT, BELGIUM--(Marketwire - April 27, 2008) - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, has announced that Dr Hennie Hoogenboom will be stepping down from his position as Chief Scientific Officer and member of the Executive Committee.
